image
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
Pier Vincenzo Piazza, CEO
Latest News
Pier Vincenzo Piazza, CEO of Aelis Farma, receives the Distinguished Achievement Award from the European Behavioural Pharmacology Society (EBPS)
August 2023
+
Aelis Farma takes part in the 10th edition of the Gordon Research Conference on the role of cannabinoid receptors in central nervous system disorders
July 2023
+